ALEC (Alector) Moat Score: 4/10 (As of Jun. 27, 2026)


ALEC Alector Inc ALEC
30 GF Score
Price $1.88
GF Value $0.73
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Alector Moat Score?

Alector ALEC +0.81% 30 Moat Score is 4 as of Jun. 27, 2026. GuruFocus rates ALEC with a GF Score™ of 30/100 and a GF Value™ of $0.73 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,404 Biotechnology companies, Alector ranks better than 88.82% on this metric.

Alector has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Alector has Narrow Moat: Alector has a discernible moat due to its focus on neurodegenerative diseases, supported by valuable intellectual property. However, it faces intense competition and lacks strong brand strength or significant customer switching costs, limiting its moat to a modest level.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Alector might have Narrow Moat - Discernible but modest moat.

Alector  (NAS:ALEC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Alector Moat Score Related Terms

ALEC vs SLGL, LENZ, CNXU: Moat Score Comparison

For the Biotechnology subindustry, Alector's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alector Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alector's Moat Score distribution charts can be found below:

* The bar in red indicates where Alector's Moat Score falls into.


ALEC
30GF Score
Alector Inc ALEC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Alector (ALEC) has a Moat Score of 4 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Alector ranks #157 out of 1404 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Alector's Moat Score too high?
Alector's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Alector's value of 4 is 100% above this industry median. Based on the distribution chart, Alector ranks #157 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alector has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alector's Moat Score compare to SLGL and LENZ?
According to the Biotechnology industry distribution chart, Alector ranks #157 out of 1404 companies for Moat Score. This places Alector in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Alector's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alector's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alector's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alector stock overvalued right now?
Based on GuruFocus' analysis, Alector (ALEC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.73, compared to a current price of $1.88 — trading 156.8% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Alector's overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Alector (ALEC), the current Moat Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alector (ALEC) Overvalued in 2026?

Based on GuruFocus' analysis, Alector stock appears to be overvalued. The current stock price of $1.88 is trading 156.8% above its estimated GF Value™ of $0.73. GuruFocus considers Alector to be Significantly Overvalued.

Key valuation signals for ALEC:

  • Moat Score: 4
  • GF Value™: $0.73 vs. price of $1.88 (156.8% above fair value)
  • GF Score™: 30/100 with 7 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1404)

No single metric tells the full story. See the ALEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alector Business Description

Address 131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
30GF Score

Get the complete analysis for ALEC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.88
Price
$0.73
GF Value